NKGen Biotech, Inc. Common Stock (NKGN) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
NKGN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, NKGen Biotech, Inc. Common Stock (NKGN) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.06 and trailing twelve-month earnings per share of $-0.82.
Compared to the Healthcare sector median P/E of 22.3x, NKGN trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, NKGN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NKGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
See NKGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NKGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NKGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNKGN — Frequently Asked Questions
Quick answers to the most common questions about buying NKGN stock.
Is NKGN stock overvalued or undervalued?
NKGN current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
How does NKGN's valuation compare to peers?
NKGen Biotech, Inc. Common Stock P/E of -0.0x compares to sector median of 22.3x. Sector comparison provides relative valuation context.
What is NKGN's PEG ratio?
NKGN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.